Results 41 to 50 of about 274,774 (268)

Single-Dose Immunogenic DNA Vaccines Coding for Live-Attenuated Alpha- and Flaviviruses

Viruses
Single-dose, immunogenic DNA (iDNA) vaccines coding for whole live-attenuated viruses are reviewed. This platform, sometimes called immunization DNA, has been used for vaccine development for flavi- and alphaviruses.
Peter Pushko, Igor S. Lukashevich, Dylan M. Johnson, Irina Tretyakova   +3 more
doaj   +1 more source

Accelerating vaccine development and deployment: report of a Royal Society satellite meeting. [PDF]

, 2011
The Royal Society convened a meeting on the 17th and 18th November 2010 to review the current ways in which vaccines are developed and deployed, and to make recommendations as to how each of these processes might be accelerated.
Bregu, Migena, Draper, Simon J, Greenwood, Brian M, Hill, Adrian VS   +3 more
core   +2 more sources

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

Emerging immunopharmacological targets in multiple sclerosis. [PDF]

, 2015
Inflammatory demyelination of the central nervous system (CNS) is the hallmark of multiple sclerosis (MS), a chronic debilitating disease that affects more than 2.5 million individuals worldwide. It has been widely accepted, although not proven, that the
Abdolmohamad Rostami, Abrams, Abrams, Achiron, Adelman, Allen, Bachmann, Bai, Bai, Baker, Balcer, Bar-Or, Bar-Or, Bar-Or, Bar-Or, Ben-Nun, Biasi, Bielekova, Bielekova, Bielekova, Bielekova, Bielekova, Bitar, Bluestone, Bogoljub Ciric, Bour-Jordan, Bourdette, Bourquin, Brambilla, Brocke, Burman, Burns, Burrows, Chaudhuri, Chitnis, Coles, Constantinescu, Constantinescu, Correale, Correale, Cox, Cragg, Crowe, Darlington, Darlington, Disanto, Duddy, Emery, Espinoza-Delgado, Faria, Faria, Farjam, Feinstein, Fissolo, Fletcher, Freedman, Garren, Garren, Garren, Garren, Giovannoni, Giovannoni, Girvin, Girvin, Goodin, Gosselin, Goverman, Goverman, Guang-Xian Zhang, Hale, Hartmann, Hauser, Havrdova, Hawker, He, Hedegaard, Higgins, Hill-Cawthorne, Hilliard, Hilliard, Ho, Hoffmann, Hofman, Jankovic, Jennum, Kappos, Kappos, Karussis, Karussis, Kearney, Kerbrat, Le Page, Li, Liblau, Lider, Lider, Lindsey, Lindsey, Lisak, Liu, Lobell, Lobell, Lohse, Lund, Lyons, Marrie, Marta, Martin, Mease, Medaer, Mestecky, Mikulkova, Miller, Milo, Mirshafiey, Mojtaba Farjam, Moreau, Mowat, Nicoletti, Nightingale, O'Brien, Offner, Offner, Oh, Oksenberg, Pender, Pettitt, Phillips, Phillips, Podojil, Poli, Pozzilli, Pryce, Quintana, Racioppi, Rasouli, Robinson, Rose, Rose, Rostami, Sandrini, Schaub, Sclerosis, Selmaj, Selmaj, Sinha, Smith, Spuler, Stuve, Taoufik, Tsunoda, Turley, Turley, Turner, van Boxel-Dezaire, van den Hoogen, Van der Walt, van Oosten, van Oosten, van Oosten, Vandenbark, Vandenbark, Viglietta, Viglietta, Vollmer, Walczak, Waldmann, Wang, Weber, Wefer, Weiner, Weiner, Weissert, Willis, Wucherpfennig, Wynn, Xing, Yadav, Zang, Zhang, Zhang, Zhang, Zhang   +182 more
core   +2 more sources

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Targeted modulation of IGFL2‐AS1 reveals its translational potential in cervical adenocarcinoma

Molecular Oncology, EarlyView.
Cervical adenocarcinoma patients face worse outcomes than squamous cell carcinoma counterparts despite similar treatment. The identification of IGFL2‐AS1's differential expression provides a molecular basis for distinguishing these histotypes, paving the way for personalized therapies and improved survival in vulnerable populations globally.
Ricardo Cesar Cintra, Lucca Paolo Hsu Helmich, Daniel Rodrigues de Bastos, Laura Sichero, Patrícia Savio de Araujo‐Souza, Fabio Passetti, Luisa Lina Villa   +6 more
wiley   +1 more source

COVID‐19 Vaccination is not Associated with the Development of Idiopathic Inflammatory Myositis in U.S. Veterans

Arthritis Care &Research, Accepted Article.
Objective Several case reports have proposed a potential association between COVID‐19 vaccination and the subsequent development of idiopathic inflammatory myositis (IIM). This study examined prior COVID‐19 vaccination in US Veterans who developed new‐onset IIM compared to those without new‐onset IIM.
Caleb Hernández, Naomi Schlesinger, Jorge Rojas, Jessica A. Walsh, Tawnie J Braaten, Gary A Kunkel, Makoto Jones, Brian C Sauer, Julio Facelli, Grant W. Cannon, Dorota Lebiedz‐Odrobina   +10 more
wiley   +1 more source

DNA Vaccines for Emerging Infectious Diseases: What If?

Emerging Infectious Diseases, 1996
A novel and powerful method for vaccine research, colloquially known as DNA vaccines, involves the deliberate introduction into tissues of a DNA plasmid carrying an antigen-coding gene that transfects cells in vivo and results in an immune response.
Robert G. Whalen
doaj   +1 more source

Lipid Nanoparticles for the Delivery of CRISPR/Cas9 Machinery to Enable Site‐Specific Integration of CFTR and Mutation‐Agnostic Disease Rescue

Advanced Functional Materials, EarlyView.
Lipid nanoparticles (LNPs) are optimized to co‐deliver Cas9‐encoding messenger RNA (mRNA), a single guide RNA (sgRNA) targeting the endogenous cystic fibrosis transmembrane conductance regulator (CFTR) gene, and homologous linear double‐stranded donor DNA (ldsDNA) templates encoding CFTR.
Ruth A. Foley, Paul G. Ayoub, Vrishti Sinha, Colin Juett, Alicia Sanoyca, Emily C. Duggan, Lindsay E. Lathrop, Priyanka Bhatt, Kevin Coote, Beate Illek, Brigitte N. Gomperts, Donald B. Kohn, Steven J. Jonas   +12 more
wiley   +1 more source

The next-generation DNA vaccine platforms and delivery systems: advances, challenges and prospects

Frontiers in Immunology
Vaccines have proven effective in the treatment and prevention of numerous diseases. However, traditional attenuated and inactivated vaccines suffer from certain drawbacks such as complex preparation, limited efficacy, potential risks and others.
Bowen Lu, Bowen Lu, Bowen Lu, Jing Ming Lim, Boyue Yu, Siyuan Song, Praveen Neeli, Navid Sobhani, Pavithra K, Srinivasa Reddy Bonam, Rajendra Kurapati, Junnian Zheng, Junnian Zheng, Dafei Chai, Dafei Chai, Dafei Chai   +15 more
doaj   +1 more source